Etid klinik pou Lupus nan Lwizyàn
9 etid pou Lupus ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50023, Baton Rouge
- Sl0044 50285, Lake Charles
- Sl0044 50660, New Orleans
Ap rekriteFaz 3
Laj 16 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06617325Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Ochsner Health System, New Orleans
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT05268289Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Accurate Clinical Research, Lake Charles
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT06133972An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, New Orleans
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 30, 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Lake Charles
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Accurate Clinical Research, Inc., Lake Charles
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07438496A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Accurate Clinical Research Inc. - Lake Charles, Lake Charles
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT07355218A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Tulane University Medical Center, New Orleans
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- University Medical Center New Orleans, New Orleans
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 21, 2026 · NCT06570798Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.